Gold ticks up but remains pressured by Fed rate caution, easing trade fears
DUBLIN - Morgan Stanley & Co. International plc disclosed on Friday its dealings in Avadel Pharmaceuticals plc (NASDAQ:AVDL) securities as required under Irish Takeover Panel rules.
According to the regulatory filing, Morgan Stanley, acting as an exempt principal trader with recognized intermediary status, conducted transactions in Avadel Pharmaceuticals ordinary shares on October 30, 2025.
The disclosure shows that Morgan Stanley purchased and sold 20 ordinary shares of Avadel Pharmaceuticals at $18.85 per share. The transactions were executed in a client-serving capacity.
The filing was made in compliance with Rule 38.5(a) of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, which requires connected exempt principal traders to disclose dealings in relevant securities during offer periods.
Morgan Stanley confirmed in the disclosure that it is connected to Avadel Pharmaceuticals in relation to an unspecified offer. The filing indicated there were no indemnity arrangements, agreements, or understandings relating to options or derivatives between the parties.
The disclosure was submitted to the Regulatory Information Service of the London Stock Exchange as required under Rule 38 of the Irish Takeover Rules.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.